All Stories

  1. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

    Article • Journal of Bone and Mineral Research, May 2018, Wiley

    Andreas Grauer

  2. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

    Article • Journal of Bone and Mineral Research, May 2018, Wiley

    Andreas Grauer

  3. colombia barranquillariesgo de fractura

    Article • Journal of Bone and Mineral Research, May 2018, Wiley

    Andreas Grauer, JUAN JALLER

  4. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

    Article • Journal of Bone and Mineral Research, June 2017, Wiley

    Andreas Grauer

  5. A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care

    Article • Journal of the American Geriatrics Society, April 2017, Wiley

    Andreas Grauer